Supplementary material: Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

dataset

posted on 2024-04-15, 13:37 authored by Josep Comin-Colet, Antoni Sicras-Mainar, Joel Salazar-Mendiguchia, Maria Alonso, Ainara Echeto, David Larena, Olga Delgado Sanchez

These are peer-reviewed supplementary materials for the article 'Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol' published in the Journal of Comparative Effectiveness Research.

Table S1: Charlson comorbidity index
Table S2: CHA2DS2-VASc score for stroke risk in atrial fibrillation
Table S3: HAS-BLED score for bleeding risk on oral anticoagulation in atrial fibrillation
Table S4: Detail of unit costs and work disability (year 2021)
Table S5: Baseline patient characteristics by study group (N = 32,925, without PSM)
Table S6: ICD-9-CM and ICD-10-CM codes used to define the results (effectiveness)

Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. Results: 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Conclusion: Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.